|
1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yano S, Wang W, Li Q, Matsumoto K,
Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka
Y, et al: Hepatocyte growth factor induces gefitinib resistance of
lung adenocarcinoma with epidermal growth factor
receptor-activating mutations. Cancer Res. 68:9479–9487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molina R, Auge JM, Filella X, Viñolas N,
Alicarte J, Domingo JM and Ballesta AM: Pro-gastrin-releasing
peptide (proGRP) in patients with benign and malignant diseases:
Comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung
cancer. Anticancer Res. 25:1773–1778. 2005.PubMed/NCBI
|
|
7
|
van Zandwijk N, Jassem E, Bonfrer JM, Mooi
WJ and van Tinteren H: Serum neuron-specific enolase and lactate
dehydrogenase as predictors of response to chemotherapy and
survival in non-small cell lung cancer. Semin Oncol. 19:(Suppl 2).
37–43. 1992.PubMed/NCBI
|
|
8
|
Diez M, Torres A, Ortega L, Maestro M,
Hernando F, Gomez A, Picardo A, Granell J and Balibrea JL: Value of
serum neuron-specific enolase in nonsmall cell lung cancer.
Oncology. 50:127–131. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pujol JL, Boher JM, Grenier J and Quantin
X: Cyfra 21-1, neuron specific enolase and prognosis of non-small
cell lung cancer: Prospective study in 621 patients. Lung Cancer.
31:221–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrigno D, Buccheri G and Giordano C:
Neuron-specific enolase is an effective tumour marker in non-small
cell lung cancer (NSCLC). Lung Cancer. 41:311–320. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viñolas N, Molina R, Galán MC, Casas F,
Callejas MA, Filella X, Grau JJ, Ballesta AM and Estape J: Tumor
markers in response monitoring and prognosis of non-small cell lung
cancer: Preliminary report. Anticancer Res. 18:631–634.
1998.PubMed/NCBI
|
|
12
|
Rider CC and Taylor CB: Evidence for a new
form of enolase in rat brain. Biochem Biophys Res Commun.
66:814–820. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fiala O, Pesek M, Finek J, Benesova L,
Minarik M, Bortlicek Z and Topolcan O: The role of neuron-specific
enolase (NSE) and thymidine kinase (TK) levels in prediction of
efficacy of EGFR-TKIs in patients with advanced-stage NSCLC.
Anticancer Res. 34:5193–5198. 2014.PubMed/NCBI
|
|
14
|
Slodkowska J, Zych J, Szturmowicz M,
Demkow U, Rowinska-Zakrzewska E and Roszkowski-Sliz K:
Neuroendocrine phenotype of non-small cell lung carcinoma:
Immunohistological evaluation and biochemical study. Int J Biol
Markers. 20:217–226. 2005.PubMed/NCBI
|
|
15
|
Sørhaug S, Steinshamn S, Haaverstad R,
Nordrum IS, Martinsen TC and Waldum HL: Expression of
neuroendocrine markers in non-small cell lung cancer. APMIS.
115:152–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Broers JL, Rot MK, Oostendorp T, Huysmans
A, Wagenaar SS, Wiersma-van Tilburg AJ, Vooijs GP and Ramaekers FC:
Immunocytochemical detection of human lung cancer heterogeneity
using antibodies to epithelial, neuronal, and neuroendocrine
antigens. Cancer Res. 47:3225–3234. 1987.PubMed/NCBI
|
|
17
|
Pujol JL, Simony J, Laurent JC, Richer G,
Mary H, Bousquet J, Godard P and Michel FB: Phenotypic
heterogeneity studied by immunohistochemistry and aneuploidy in
non-small cell lung cancers. Cancer Res. 49:2797–2802.
1989.PubMed/NCBI
|
|
18
|
Kibbelaar RE, Moolenaar KE, Michalides RJ,
Van Bodegom PC, Vanderschueren RG, Wagenaar SS, Dingemans KP,
Bitter-Suermann D, Dalesio O, Van Zandwijk N, et al: Neural cell
adhesion molecule expression, neuroendocrine differentiation and
prognosis in lung carcinoma. Eur J Cancer. 27:431–435. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Graziano SL, Mazid R, Newman N, Tatum A,
Oler A, Mortimer JA, Gullo JJ, DiFino SM and Scalzo AJ: The use of
neuroendocrine immunoperoxidase markers to predict chemotherapy
response in patients with non-small-cell lung cancer. J Clin Oncol.
7:1398–1406. 1989.PubMed/NCBI
|
|
20
|
Pujol JL, Simony J, Demoly P, Charpentier
R, Laurent JC, Daurès JP, Lehmann M, Guyot V, Godard P and Michel
FB: Neural cell adhesion molecule and prognosis of surgically
resected lung cancer. Am Rev Respir Dis. 148:1071–1075. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hiroshima K, Iyoda A, Shibuya K, Toyozaki
T, Haga Y, Fujisawa T and Ohwada H: Prognostic significance of
neuroendocrine differentiation in adenocarcinoma of the lung. Ann
Thorac Surg. 73:1732–1735. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pelosi G, Pasini F, Sonzogni A, Maffini F,
Maisonneuve P, Iannucci A, Terzi A, De Manzoni G, Bresaola E and
Viale G: Prognostic implications of neuroendocrine differentiation
and hormone production in patients with Stage I nonsmall cell lung
carcinoma. Cancer. 97:2487–2497. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Howe MC, Chapman A, Kerr K, Dougal M,
Anderson H and Hasleton PS: Neuroendocrine differentiation in
non-small cell lung cancer and its relation to prognosis and
therapy. Histopathology. 46:195–201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Linnoila RI, Piantadosi S and Ruckdeschel
JC: Impact of neuroendocrine differentiation in non-small cell lung
cancer. The LCSG experience. Chest. 106:(Suppl 6). 367S–371S. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hage R, Elbers HR, Brutel de la Rivière A
and van den Bosch JM: Neural cell adhesion molecule expression:
Prognosis in 889 patients with resected non-small cell lung cancer.
Chest. 114:1316–1320. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haimoto H, Takahashi Y, Koshikawa T,
Nagura H and Kato K: Immunohistochemical localization of
gamma-enolase in normal human tissues other than nervous and
neuroendocrine tissues. Lab Invest. 52:257–263. 1985.PubMed/NCBI
|
|
27
|
Shibayama T, Ueoka H, Nishii K, Kiura K,
Tabata M, Miyatake K, Kitajima T and Harada M: Complementary roles
of pro-gastrin-releasing peptide (ProGRP) and neuron specific
enolase (NSE) in diagnosis and prognosis of small-cell lung cancer
(SCLC). Lung Cancer. 32:61–69. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nisman B, Biran H, Ramu N, Heching N,
Barak V and Peretz T: The diagnostic and prognostic value of ProGRP
in lung cancer. Anticancer Res. 29:4827–4832. 2009.PubMed/NCBI
|
